Verffentlichungsdatum: 2015-10-13 Rated 4 von 5 von Anonymous aus Der Geruch
A Dual-Action Approach to Inflammation and Metabolic Health These results add to growing evidence that metabolic health and autoimmune disease activity are closely linked
Data from a large retrospective cohort study to be presented at the 2026 American Society of Clinical Oncology (ASCO) Breakthrough Meeting showed that GLP-1 receptor agonist (GLP-1 RA) use was significantly associated with lower colorectal cancer incidence among patients with inflammatory bowel disease (IBD), including those with comorbid type 2 diabetes (T2D)
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K
Therefore, localized immunometabolic disturbances, particularly defective butyrate metabolism and dysregulated tryptophan catabolism, disrupt the Th17/Treg balance and compromise epithelial integrity in IBD, underscoring the gut microbiome and microbial metabolites as actionable therapeutic targets
